

1996), spindle function (Glover *et al.*, 1996), activation of cyclin B/Cdc2 (Qian *et al.*, 1998; Toyoshima-Morimoto *et al.*, 2001), and regulation of anaphase-promoting complex (Kotani *et al.*, 1998; Nigg, 1998). Elevated expression of *PLK1* is also found in different types of adult cancers including non-small-cell lung cancer, head and neck tumors, esophageal carcinomas, melanomas, and colorectal cancers (Wolf *et al.*, 1997; Knecht *et al.*, 1999; Tokumitsu *et al.*, 1999; Dietzmann *et al.*, 2001; Takai *et al.*, 2001), implying its critical role in tumorigenesis. In the present study, we have found that *PLK1* is upregulated in primary HBLs, and that its mRNA expression levels are significantly correlated with poor outcome of the patients. Multivariate Cox regression analysis indicated that *PLK1* expression could be an independent prognostic factor from  $\beta$ -catenin mutation, age, stage, or histology. However, clinical stage did not show a significant correlation with *PLK1* expression, though it is one of the critical prognostic markers. One of the possible reasons may be that the 59 tumors we used for statistical analysis include two unusual patients, one had stage 4 tumor with good prognosis and another case had stage 1 tumor with poor prognosis. These might have reduced the significance of the tumor stage in patients' survival in our sample set.

It is notable that, among the 1188 genes we have screened for differential expression, *PLK1* is the only one known oncogene overexpressed in the HBL tissues. Smith *et al.* (1997) have reported that constitutive expression of *PLK1* in NIH3T3 cells causes oncogenic focus formation and forms tumors in nude mice. Furthermore, Liu and Erikson (2003) have recently shown that the application of small interfering RNA which specifically depletes *PLK1* expression in cancer cells inhibits cell proliferation, arrests cell cycle, and induces apoptosis. Thus, *PLK1* may play a crucial role in causing HBL and other cancers. It may be interesting to examine whether *PLK1* is a target of  $\beta$ -catenin transported from the cytosol into the nucleus. The disruption of *PLK1* function could be a future therapeutic tool for the aggressive type of hepatoblastomas.

In conclusion, our HBL cDNA project has provided a large number of genes related to liver development, metabolism, and carcinogenesis. We are currently applying these genes to the cDNA microarray system. Our cDNA resource should be an important tool to understand the molecular mechanism of the genesis of HBL as well as to develop new diagnostic and therapeutic strategies against the aggressive tumors in the future.

## Materials and methods

### Clinical materials

Tumor tissues and their corresponding normal liver tissues were frozen at the time of surgery and stored at  $-80^{\circ}\text{C}$  until use. All specimens were provided from the Tissue Bank of the Japanese Study Group for Pediatric Liver Tumor (JPLT)

(Uotani *et al.*, 1998). A total of 74 HBL samples (seven were classified as being stage 1, 17 as stage 2, 26 as stage 3, 15 as stage 4, and nine were unknown stages) were used in this study. The tumors were staged according to the Japanese histopathological classification of HBL (Hata, 1990). From 1991 to 1999, HBLs had been treated by combination chemotherapy using cisplatin and THP-adriamycin according to the JPLT-1 protocol (Sasaki *et al.*, 2002). After 2000, a more intensive chemotherapeutic regimen, ITEC (ifosfamide, THP-adriamycin, etoposide, and carboplatin), has been utilized for tumors that prove resistant to the combination chemotherapy in the JPLT-2 study. Among the 74 tumor samples we examined, 36 and 35 tumor tissues were obtained prior to and after chemotherapy, respectively, and the remaining three were unknown. In the same sample set, 59 tumors were accompanied by outcome information and used for making survival curves, among which 31 and 28 tissues were obtained prior to and after chemotherapy, respectively. Tumor histology was also classified according to Hata (1990). 'Poor histology' indicates 'poorly differentiated (embryonal type)', and 'well histology' indicates 'well-differentiated (fetal type)'. The informed consents were obtained in each institution or hospital. High molecular weight DNA and total RNA of these samples were prepared as described previously (Ichimiya *et al.*, 1999).

### Construction of oligo-capping cDNA libraries

Four oligo-capping cDNA libraries, two (HMFT, HYST) derived from HBLs with secretion of AFP, one (HKMT) from HBL without AFP secretion, and one (HMFN) from the corresponding normal liver, were constructed according to the method previously described (Suzuki *et al.*, 1997). These were approved by the institutional review board. The oligo-capping method enables full-length cDNA cloning with high efficiency. The 12000 cDNA clones in total were randomly picked up and single-run sequencing was performed. Nucleotide sequence of both ends for each cDNA clone was homology-searched against the public nucleotide database using the BLAST program at the National Center for Biotechnology Information (NCBI) (Genbank release 122, January 2001).

### Differential screening of the genes by semi-quantitative RT-PCR

The eight samples were selected as PCR templates to screen for the differentially expressed genes. Cases 58 and 81 were defined as stage 2 HBL, cases 10, 67, 78, and 85 were in stage 3, case 14 was in stage 4. Among those eight tumors, four (cases 14, 67, 78, and 81) had the mutant  $\beta$ -catenin, and the others (cases 10, 58, 77, and 85) not. Mutation analysis for  $\beta$ -catenin was performed as described previously (Takayasu *et al.*, 2001). The differential expression of the genes between the HBL and normal livers was confirmed at least twice using semi-quantitative RT-PCR. The individual gene-specific PCR primer sequences were determined by using Primer3 program (provided at Washington University). For cDNA templates, 5  $\mu\text{g}$  of total RNA was converted to cDNA using random primers (Takara, Otsu, Japan) with SuperScript II RNaseH<sup>-</sup> reverse transcriptase (Gibco BRL, Rockville, MD, USA). Those cDNAs were at first amplified with *GAPDH* primers for 27 cycles and the amounts of the PCR products were measured by ALF Express<sup>™</sup> sequencer and normalized. The amplification was performed 35 or 40 cycles of  $95^{\circ}\text{C}$  for 30 s, 57 or 59 or  $61^{\circ}\text{C}$  for 15 s and  $72^{\circ}\text{C}$  for 60 s, and the final extension was at  $72^{\circ}\text{C}$  for 5 min, using a Perkin-Elmer Thermalcycler 9700 (Perkin-Elmer, Foster City, CA, USA). The PCR products

were run on 2% agarose gels and stained with ethidium bromide. We defined the gene as differentially expressed when it exhibits differential expression between the tumor and its corresponding normal liver in more than four out of the eight samples.

#### Northern blot analysis

In all, 25 µg of total RNA from the primary HBLs, HCC, and their corresponding normal livers were subjected to Northern analysis. Total RNA was prepared according to the method of Chomczynski and Sacchi (1987). Total RNA was fractionated by electrophoresis on 1% agarose gel containing formaldehyde, transferred onto a nylon membrane filter, and immobilized by UV crosslinking. The hybridization cDNA probe was a 976-base pair human *PLK1* cDNA fragment and labeled with [ $\alpha$ -<sup>32</sup>P]-dCTP using the BcaBEST random priming kit (Takara Biomedicals). The filter was hybridized at 65°C in a solution containing 1 M NaCl, 1% SDS, 7.5% dextran sulfate, 100 µg/ml of heat-denatured salmon sperm DNA, and radiolabeled probe DNA.

#### Quantitative real-time RT-PCR of *PLK1*

The primer set for amplification of the *PLK1* and probe sequence are as follows: forward primer, 5'-GCTGCACAAGAGGAGGAAA-3'; reverse primer, 5'-AGCTTGAGGTCTC-GATGAATAAC-3'; probe, 5'-CCTGACTGAGCCTGAGGCCGATAC-TA-3'. Taqman *GAPDH* control reagents (Perkin-Elmer/Applied Biosystems) were used for the amplification of *GAPDH* as recommended by the manufacturer. PCR was performed using ABI Prism 7700 Sequence Detection System

(Perkin-Elmer/Applied Biosystems). In all, 2 µl of cDNA was amplified in a final volume of 25 µl containing 1 × Taqman PCR reaction buffer, 200 µM each dNTP, 0.9 µM each primer, and 200 nM Taqman probe. The optional thermal cycling condition was as follows: 40 cycles of a two-step PCR (95°C for 15 s, 60°C for 60 s) after the initial denaturation (95°C for 10 min). Experiments were carried out in triplicate for each data point.

#### Statistical analysis

Statistical analyses were performed using Mann-Whitney's U-test and Cox regression. A P-value of less than 0.05 was considered significant.

#### Acknowledgements

We are grateful to Shigeru Sakiyama and Toshinori Ozaki for critical reading of the manuscript, and Yoko Nakamura and Aiko Morohashi for experimental support. We thank Eriko Isogai, Naoko Sugimitsu, and Yuki Nakamura for preparing RNA and sequencing analysis, and Natsue Kitabayashi, Emiko Kojima, Emi Goto, and Hisae Murakami for technical assistance. We also thank the hospitals and institutions collaborating with the Japanese Study Group for Pediatric Liver Tumor (JPLT) for providing surgical specimens. This work was supported in part by the fund from Hisamitsu Pharmaceutical Company and a grant-in-aid for Scientific Research on Priority Areas (C) 'Medical Genome Science' from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.

#### References

- Albrecht S, Von Schweinitz D, Waha A, Kraus JA, Von Deimling A and Pietsch T. (1994). *Cancer Res.*, **54**, 5041-5044.
- Brady RO, Filling-Katz MR, Barton NW and Pentchev PG. (1989). *Neurol. Clin.*, **7**, 75-88.
- Buendia MA. (1992). *Adv. Cancer Res.*, **59**, 167-226.
- Buendia MA. (2002). *Med. Pediatr. Oncol.*, **39**, 530-535.
- Chomczynski P and Sacchi N. (1987). *Anal. Biochem.*, **162**, 156-159.
- Clay FJ, McEwen SJ, Bertocello I, Wilks AF and Dunn AR. (1993). *Proc. Natl. Acad. Sci. USA*, **90**, 4882-4886.
- Dietzmann K, Kirches E, Von Bossanyi, Jachau K and Mawrin C. (2001). *J. Neurooncol.*, **53**, 1-11.
- Exelby PR, Filler RM and Grosfeld JL. (1975). *J. Pediatr. Surg.*, **10**, 329-337.
- Fukuzawa R, Umezawa A, Ochi K, Urano F, Ikeda H and Hata J. (1999). *Int. J. Cancer*, **82**, 490-497.
- Giardiello FM, Petersen GM, Brensinger JD, Luce MC, Cayouette MC, Bacon J, Booker SV and Hamilton SR. (1996). *Gut*, **39**, 867-869.
- Glover DM, Ohkura H and Tavares A. (1996). *J. Cell Biol.*, **135**, 1681-1684.
- Goldstein JL and Brown MS. (1990). *Nature*, **343**, 425-430.
- Gray SG, Eriksson T, Ekstrom C, Holm S, Von Schweinitz D, Kogner P, Sandstedt B, Pietsch T and Ekstrom TJ. (2000). *Br. J. Cancer*, **82**, 1561-1567.
- Haas JE, Muczynski KA, Krailo M, Ablin A, Land V, Vietti TJ and Hammond GD. (1989). *Cancer*, **64**, 1082-1095.
- Hamanaka R, Kohno K, Seguchi T, Okamura K, Morimoto A, Ono M, Ogata J and Kuwano M. (1992). *J. Biol. Chem.*, **267**, 13160-13165.
- Hata Y. (1990). *Jpn. J. Surg.*, **20**, 498-502.
- Hata Y, Ishizu H, Ohmori K, Hamada H, Sasaki F, Uchino J, Inoue K, Naitoh H, Fujita M, Kobayashi T and Yokoyama S. (1991). *Cancer*, **68**, 2566-2570.
- Hsieh JC, Kodjabachian L, Rebbert ML, Rattner A, Smallwood PM, Samos CH, Nusse R, Dawid IB and Nathans J. (1999). *Nature*, **398**, 431-436.
- Ichimiya S, Nimura Y, Kageyama H, Takada N, Sunahara M, Shishikura T, Nakamura Y, Sakiyama S, Seki N, Ohira M, Kaneko Y, McKeon F, Caput D and Nakagawara A. (1999). *Oncogene*, **18**, 1061-1066.
- Idilman R, De Maria N, Colantoni A and Van Thiel DH. (1998). *J. Viral. Hepat.*, **5**, 285-299.
- Kinoshita M and Miyata M. (2002). *Hepatology*, **36**, 433-438.
- Kinzler KW and Vogelstein B. (1996). *Cell*, **87**, 159-170.
- Knecht R, Elez R, Oechler M, Solbach C, Von Ilberg C and Strebhardt K. (1999). *Cancer Res.*, **59**, 2794-2797.
- Koch A, Denkhau D, Albrecht S, Leuschner I, Von Schweinitz D and Pietsch T. (1999). *Cancer Res.*, **59**, 269-273.
- Kotani S, Tugendreich S, Fujii M, Jorgensen PM, Watanabe N, Hoog C, Hieter P and Todokoro K. (1998). *Mol. Cell*, **1**, 371-380.
- Lane HA and Nigg EA. (1996). *J. Cell Biol.*, **135**, 1701-1713.
- Li FP, Wendy AT, Seddon J and Holmes GE. (1987). *J. Am. Med. Assoc.*, **257**, 2475-2477.
- Li X, Adam G, Cui H, Sandstedt B, Ohlsson R and Ekstrom TJ. (1995). *Oncogene*, **11**, 221-229.
- Liu X and Erikson RL. (2003). *Proc. Natl. Acad. Sci. USA*, **100**, 5789-5794.

- Loftus SK, Morris JA, Carstea ED, Gu JZ, Cummings C, Brown A, Ellison J, Ohno K, Rosenfeld A, Tagle DA, Pentchev PG and Pavan WJ. (1997). *Science*, **277**, 232-235.
- Mann JR, Lakin GE, Leonard JC, Rawlinson HA, Richardson SG, Corkery JJ, Cameron AH and Shah KJ. (1978). *Arch. Dis. Child*, **53**, 366-374.
- Miao J, Kusafuka T, Udatsu Y and Okada A. (2003). *Hepatol. Res.*, **25**, 174-179.
- Montagna M, Menin C, Chieco-Bianchi L and D'Andrea E. (1994). *J. Cancer Res. Clin. Oncol.*, **120**, 732-736.
- Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B and Kinzler KW. (1997). *Science*, **275**, 1787-1790.
- Nagata T, Takahashi Y, Ishii Y, Asai S, Nishida Y, Murata A, Koshinaga T, Fukuzawa M, Hamazaki M, Asami K, Ito E, Ikeda H, Takamatsu H, Koike K, Kikuta A, Kuroiwa M, Watanabe A, Kosaka Y, Fujita H, Miyake M and Mugishima H. (2003). *Cancer Genet. Cytogenet.*, **145**, 152-160.
- Nigg EA. (1998). *Curr. Opin. Cell Biol.*, **10**, 776-783.
- Oda H, Nakatsuru Y, Imai Y, Sugimura H and Ishikawa T. (1995). *Int. J. Cancer*, **60**, 786-790.
- Oda H, Imai Y, Nakatsuru Y, Hata J and Ishikawa T. (1996). *Cancer Res.*, **56**, 3320-3323.
- Okabe H, Satoh S, Kato T, Kitahara O, Yanagawa R, Yamaoka Y, Tsunoda T, Furukawa Y and Nakamura Y. (2001). *Cancer Res.*, **61**, 2129-2137.
- Okubo K, Hori N, Matoba R, Niiyama T, Fukushima A, Kojima Y and Matsubara K. (1992). *Nat. Genet.*, **2**, 173-179.
- Ortega JA, Krailo MD, Haas JE, King DR, Ablin AR, Quinn JJ, Feusner J, Campbell JR, Lloyd DA, Cherlow J and Hammond GD. (1991). *J. Clin. Oncol.*, **9**, 2167-2176.
- Park WS, Oh RR, Park JY, Kim PJ, Shin MS, Lee JH, Kim HS, Lee SH, Kim SY, Park YG, An WG, Kim HS, Jang JJ, Yoo NJ and Lee JY. (2001). *J. Pathol.*, **193**, 483-490.
- Polakis P. (1999). *Curr. Opin. Genet. Dev.*, **9**, 15-21.
- Qian YW, Erikson E, Li C and Maller JL. (1998). *Mol. Cell. Biol.*, **18**, 4262-4271.
- Rainier S, Dobry CJ and Feinberg AP. (1995). *Cancer Res.*, **55**, 1836-1838.
- Ribbeck K, Lipowsky G, Kent HM, Stewart M and Gorlich D. (1998). *EMBO J.*, **17**, 6587-6598.
- Rimm DL, Caca K, Hu G, Harrison FB and Fearon ER. (1999). *Am. J. Pathol.*, **154**, 325-329.
- Ryazanov AG, Pavur KS and Dorovkov MV. (1999). *Curr. Biol.*, **9**, R43-45.
- Sasaki F, Matsunaga T, Iwafuchi M, Hayashi Y, Ohkawa H, Ohira M, Okamatsu T, Sugito T, Tsuchida Y, Toyosaka A, Nagahara N, Nishihira H, Hata Y, Uchino J, Misugi K and Ohnuma N. (2002). *J. Pediatr. Surg.*, **37**, 851-856.
- Smith MR, Wilson ML, Hamanaka R, Chase D, Kung H, Longo DL and Ferris DK. (1997). *Biochem. Biophys. Res. Commun.*, **234**, 397-405.
- Sudhof TC, Russell DW, Brown MS and Goldstein JL. (1987). *Cell*, **48**, 1061-1069.
- Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, Suyama A and Sugano S. (1997). *Gene*, **200**, 149-156.
- Takai N, Miyazaki T, Fujisawa K, Nasu K, Hamanaka R and Miyakawa I. (2001). *Cancer Lett.*, **164**, 41-49.
- Takayasu H, Horie H, Hiyama E, Matsunaga T, Hayashi Y, Watanabe Y, Suita S, Kaneko M, Sasaki F, Hashizume K, Ozaki T, Furuuchi K, Tada M, Ohnuma N and Nakagawa A. (2001). *Clin. Cancer Res.*, **7**, 901-908.
- Taniguchi K, Roberts LR, Aderca IN, Dong X, Qian C, Murphy LM, Nagorney DM, Burgart LJ, Roche PC, Smith DI, Ross JA and Liu W. (2002). *Oncogene*, **21**, 4863-4871.
- Thomas D, Pritchard J, Davidson R, McKiernan P, Grundy RG and de Ville de Goyet J. (2003). *Eur. J. Cancer*, **39**, 2200-2204.
- Tokumitsu Y, Mori M, Tanaka S, Akazawa K, Nakano S and Niho Y. (1999). *Int. J. Oncol.*, **15**, 687-692.
- Toyoshima-Morimoto F, Taniguchi E, Shinya N, Iwamatsu A and Nishida E. (2001). *Nature*, **410**, 215-220.
- Uotani H, Yamashita Y, Masuko Y, Shimoda M, Murakami A, Sakamoto T, Tazawa K and Tsukada K. (1998). *J. Pediatr. Surg.*, **33**, 639-641.
- Van Tornout JM, Buckley JD, Quinn JJ, Feusner JH, Krailo MD, King DR, Hammond GD and Ortega JA. (1997). *J. Clin. Oncol.*, **15**, 1190-1197.
- Velculescu VE, Vogelstein B and Kinzler KW. (2000). *Trends Genet.*, **16**, 423-425.
- Von Horn H, Tally M, Hall K, Eriksson T, Ekstrom TJ and Gray SG. (2001). *Cancer Lett.*, **162**, 253-260.
- Von Schweinitz D, Hecker H, Harms D, Bode U, Weinel P, Burger D, Erttmann R and Mildenerberger H. (1995). *J. Pediatr. Surg.*, **30**, 845-852.
- Von Schweinitz D, Wischmeyer P, Leuschner I, Schmidt D, Wittekind C, Harms D and Mildenerberger H. (1994). *Eur. J. Cancer*, **30A**, 1052-1058.
- Wang J, Shou J and Chen X. (2000). *Oncogene*, **19**, 1843-1848.
- Weber RG, Pietsch T, Von Schweinitz D and Lichter P. (2000). *Am. J. Pathol.*, **157**, 571-578.
- Wei Y, Fabre M, Branchereau S, Gauthier F, Perilongo G and Buendia MA. (2000). *Oncogene*, **19**, 498-504.
- Weinberg AG and Finegold M. (1983). *Hum. Pathol.*, **14**, 512-537.
- Wissmann C, Wild PJ, Kaiser S, Roepcke S, Stoehr R, Woenckhaus M, Kristiansen G, Hsieh JC, Hartmann A, Knuedel R, Rosenthal A and Pilarsky C. (2003). *J. Pathol.*, **201**, 204-212.
- Wolf G, Elez R, Doermer A, Holtrich U, Ackermann H, Stutte HJ, Altmannsberger HM, Rubsamen-Waigmann H and Strebhardt K. (1997). *Oncogene*, **14**, 543-549.
- Xu XR, Huang J, Xu ZG, Qian BZ, Zhu ZD, Yan Q, Cai T, Zhang X, Xiao HS, Qu J, Liu F, Huang QH, Cheng ZH, Li NG, Du JJ, Hu W, Shen KT, Lu G, Fu G, Zhong M, Xu SH, Gu WY, Huang W, Zhao XT, Hu GX, Gu JR, Chen Z and Han ZG. (2001). *Proc. Natl. Acad. Sci. USA*, **98**, 15089-15094.
- Yun K, Jinno Y, Sohda T, Niikawa N and Ikeda T. (1998). *J. Pathol.*, **185**, 91-98.

## Usefulness of Tyrosine Hydroxylase mRNA for Diagnosis and Detection of Minimal Residual Disease in Neuroblastoma

Rie ITO,<sup>a</sup> Satoru ASAMI,<sup>a</sup> Shigeki KAGAWA,<sup>a</sup> Shigeyasu MOTOHASHI,<sup>b</sup> Hiroyuki SHICHINO,<sup>c</sup> Motoaki CHIN,<sup>c</sup> Yukihiro YOSHIDA,<sup>d</sup> Norimichi NEMOTO,<sup>e</sup> Hideo MUGISHIMA,<sup>c,f</sup> and Takashi SUZUKI<sup>\*a,c</sup>

<sup>a</sup> Clinical Pharmacy, College of Pharmacy, Nihon University; <sup>b</sup> Chemistry, College of Pharmacy, Nihon University; 7-7-1 Narashinodai, Funabashi, Chiba 274-8555, Japan; <sup>c</sup> Department of Pediatrics, School of Medicine, Nihon University; <sup>d</sup> Department of Orthopedics, School of Medicine, Nihon University; <sup>e</sup> Department of Pathology, School of Medicine, Nihon University; and <sup>f</sup> Department of Advanced Medicine, Division of Cell Regeneration and Transplantation, School of Medicine, Nihon University; 30-1 Oyaguchikami-cho, Itabashi-ku, Tokyo 173-0032, Japan.

Received October 31, 2003; accepted December 17, 2003

Neuroblastoma (NB) is the most common malignant solid tumor in childhood and, among all childhood malignancies, is second only to leukemia. NB originates before birth in the neural crest, which develops into the adrenal medullae and sympathetic ganglia. In the adrenal medulla, tyrosine hydroxylase (TH) is the first enzyme in the pathway of catecholamine synthesis. We used reverse transcription polymerase chain reaction (RT-PCR) to examine the expression of TH mRNA in NB and Ewing's sarcoma cell lines, small round cell tumors (SRCTs) containing NB, and other clinical tumor samples (osteosarcoma, osteochondroma, and Wilms' tumor). In total, we analyzed 33 clinical tumor samples. TH mRNA was expressed in all three NB cell lines examined, but not in two ES cell lines or in a breast cancer cell line. We detected TH mRNA in 23 of 25 NB tumor samples (92%), but in none of the SRCTs or other clinical tumor samples. This RT-PCR technique showed a sensitivity for TH mRNA of one NB cell per 10<sup>5</sup> negative cells. Based on these results, the detection of TH mRNA is very useful both as a tumor marker for NB and for detecting minimal residual disease. Therefore, we can use this method to detect tumor cell contamination before hematopoietic stem cell transplantation.

**Key words** neuroblastoma; tyrosine hydroxylase; hematopoietic stem cell transplantation; minimal residual disease; reverse transcription polymerase chain reaction

Neuroblastoma (NB) is a very common malignant solid tumor in childhood. NB belongs to the small round cell tumors (SRCTs), which include other solid tumors such as Ewing's sarcoma (ES), rhabdomyosarcoma, and malignant lymphoma.<sup>1)</sup> SRCTs are histologically ambiguous, so it is necessary to analyze adequate tumor markers for an accurate diagnosis. Patients who are over the age of 1 year at diagnosis usually have poor prognoses.<sup>2)</sup>

NB is also characterized by elevated levels of catecholamine production. Tyrosine hydroxylase (TH) is very important as the first and rate-limiting step in the synthesis of catecholamines.<sup>3–6)</sup> Therefore, we used reverse transcription polymerase chain reaction (RT-PCR) to examine the expression of TH mRNA in some cell lines, SRCTs, and other clinical tumor samples, to assess whether we can use it as a tumor marker and detect cell contamination in hematopoietic stem cells. Specific TH mRNA could be detected in NB cell lines and clinical NB tumor samples, but not in other cell lines and tumor samples. Moreover, the technique had a high sensitivity of 1/10<sup>5</sup>.

We think that this method should be used for detecting minimal residual disease because the prognoses of patients in NBs depend on being positive or negative for TH mRNA in bone marrow (BM) samples within 4 months after chemotherapy.<sup>7)</sup> Moreover, the risk of relapse after autologous peripheral blood stem cell (PBSC) or BM transplantation is high if there is NB cell contamination.<sup>8,9)</sup>

Here, we describe a very useful method for detecting minimal residual disease. The method can also be used as a tumor marker.

### MATERIALS AND METHODS

**Cell Lines and Tumor Samples** Three NB cell lines (IMR-32,<sup>10,12)</sup> SK-N-SH,<sup>11,12)</sup> and NB-39,<sup>12)</sup> two ES cell lines (NCR-EW2,<sup>13)</sup> SCMC-ES1<sup>14)</sup>, and one breast cancer cell line (MCF-7<sup>15)</sup>) were examined. They were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 0.1 mg/ml streptomycin, and 2 g/l sodium bicarbonate under 5% CO<sub>2</sub> at 37°C. Thirty-three clinical tumor samples (25 NBs, 1 ES, 1 osteosarcoma, 1 osteochondroma, 1 Wilms' tumor, 1 malignant lymphoma, and 3 rhabdomyosarcoma) were examined. One of the three rhabdomyosarcoma samples was from a recurrent tumor. These tissues had been stored at –80°C since collection. The clinical diagnoses for these patients were made by histopathology. Informed consent was obtained from all patients before they entered this study.

**RNA Extraction** Total RNA was extracted from the six cell lines using the acid-guanidium-phenol chloroform method after treatment with Catrimox-14<sup>TM</sup>. Total RNA from the 33 clinical tumor samples was extracted by TRIZOL reagent (GIBCO BAL) based on the acid-guanidium-phenol chloroform extraction method.<sup>16)</sup>

**Reverse Transcription Polymerase Chain Reaction** Total RNA (1 µg) was reverse-transcribed in a 10 µl reaction mixture with a first strand cDNA synthesis kit (Rever Tra-α-TM, TOYOBO). RT was performed with Oligo-dT. The mixture was annealing at 42°C for 20 min, followed by incubated at 99°C for 5 min, and then held at 4°C. PCR amplification was carried out in 10× reaction mixture containing 1.2 pmol of the respective primers. We used a HOT START PCR kit from KOD-Plus- (TOYOBO).<sup>17–19)</sup> The PCR conditions were one cycle of template denaturing at 94°C for

\* To whom correspondence should be addressed. e-mail: suzuki@pha.nihon-u.ac.jp

Table 1. PCR Primers

Gene	Sequence	Location
TH sense	5'-TGT CAG AGC TGG ACA AGT GT-3'	Exon 8
TH anti-sense	5'-GAT ATT GTC TTC CCG GTA GC-3'	Exon 9
GAPDH sense	5'-TCC TCT GAC TTC AAC AGC GAC ACC-3'	Exon 5
GAPDH anti-sense	5'-TCT CTC TTC CTC TTG TGC TCT TGG-3'	Exon 8

2 min, followed by 28 cycles of denaturing at 94 °C for 15 s, annealing at 60 °C for 90 s, extension at 68 °C for 20 s, and then holding at 4 °C. We used glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as an internal marker and IMR-32, NB-39, and SK-N-SH neuroblastoma cell lines as positive controls. NCR-EW2, SCMC-ES1, and MCF-7 were examined as negative controls. The primer sequences are listed in Table 1.<sup>20)</sup> The primers for TH are located in exons that are not affected by alternative splicing. To avoid contamination with genomic DNA, the reverse primers for both TH and GAPDH were located in successive exons.

**Analyses of PCR Products** The PCR products were electrophoresed through 2.0% agarose gel, stained with ethidium bromide (WAKO), and visualized under a UV lamp. We used a Bioanalyzer (Agilent Technologies) to accurately determine band sizes.

**Detection for Sensitivity** A NB cell line (IMR-32) was examined as a positive control and an ES cell line (NCR-EW2) as a negative control. We counted the number of each cell type and diluted them to make suspensions containing one NB cell per 10 ES cells, one per 10<sup>2</sup>, one per 10<sup>3</sup>, one per 10<sup>4</sup>, one per 10<sup>5</sup>, and one per 10<sup>6</sup>. We investigated the sensitivity of this RT-PCR technique for detecting TH mRNA.

## RESULTS AND DISCUSSION

We analyzed six cell lines for detecting a specific TH mRNA with the RT-PCR technique. The electrophoresis and Bioanalyzer results are presented in Figs. 1A and 1B. The band size for TH was 299 bp, and the internal marker GAPDH was 209 bp. TH mRNA was detected in three NB cell lines (IMR-32, NB-39, and SK-N-SH), but it was not detected in the ES cell lines (NCR-EW2, SCMC-ES1) or the breast cancer cell line (MCF-7).

We investigated 33 clinical tumor samples by the same method as that used for the cell lines. The electrophoresis and Bioanalyzer results are presented in Tables 2 and 3. In 23 of 25 NB tumor samples (92%), TH mRNA could be detected, but it was not detected in the T1 and T2 samples (Table 2). TH mRNA was not detected in the osteosarcoma (T26), osteochondroma (T27), Wilms' tumor (T28), and SRCT (T29—T33) samples (Table 3). The rhabdomyosarcoma from a recurrent tumor (T33) also did not express TH mRNA.

We examined the sensitivity for detecting minimal residual disease by this RT-PCR technique. We used a NB cell line (IMR-32) as a positive control and an ES cell line (NCR-EW2) as a negative control. The electrophoresis and Bioanalyzer results are presented in Figs. 2A and 2B. On the electrophoresis, a TH mRNA band could be seen in samples with concentrations down to one NB cell per 10<sup>5</sup> ES cells, but not at a concentration of one NB cell per 10<sup>6</sup> ES cells (Fig. 2A).




Fig. 1. RT-PCR Products Detected in Cell Lines

(A) Bands detected by electrophoresis. Lane 1, marker; lane 2, IMR-32; lane 3, NB-39; lane 4, SK-N-SH; lane 5, NCR-EW2; lane 6, SCMC-ES1; lane 7, MCF-7. (B) Bands detected by Bioanalyzer. Lanes are as for electrophoresis. A 299 bp RT-PCR product for TH was seen by both electrophoresis and Bioanalyzer, and a 209 bp product for GAPDH was also seen.

Table 2. NB Patients' Clinical Profile and TH mRNA Bands Detected by Electrophoresis and Bioanalyzer

Tissue	Sex	Age	Diagnosis	TH mRNA
T1	F	1 y	NB	-
T2	F	10 m	NB	-
T3	M	10 m	NB	+
T4	M	10 m	NB	+
T5	M	9 m	NB	+
T6	M	3 y	NB	+
T7	M	7 m	NB	+
T8	M	4 m	NB	+
T9	F	10 m	NB	+
T10	F	1 y	NB	+
T11	F	6 y	NB	+
T12	F	1 y	NB	+
T13	F	8 m	NB	+
T14	F	6 m	NB	+
T15	M	4 y	NB	+
T16	F	3 y	NB	+
T17	M	4 y	NB	+
T18	F	10 y	NB	+
T19	M	9 y	NB	+
T20	F	7 m	NB	+
T21	F	9 m	NB	+
T22	F	10 m	NB	+
T23	M	3 y	NB	+
T24	M	5 y	NB	+
T25	F	5 y	NB	+

NB: neuroblastoma.

Similarly, using the Bioanalyzer, TH mRNA could be detected at one NB cell per 10<sup>5</sup> ES cells but not at one NB cell per 10<sup>6</sup> ES cells (Fig. 2B).

Abnormal amplification and expression are well known for *MYCN*,<sup>21-23)</sup> *irk-A*,<sup>24-27)</sup> and protein gene product 9.5 (PGP9.5)<sup>28)</sup> in NB. However, these markers are not very useful for diagnosis. Recently, by using monoclonal antibodies

Table 3. Other Tumor Patients' Clinical Profile and TH mRNA Bands Detected by Electrophoresis and Bioanalyzer

Tissue	Sex	Age	Diagnosis	TH mRNA
T26	M	13 y	OS	-
T27	F	12 y	OC	-
T28	M	8 m	WT	-
T29	F	6 m	ML	-
T30	M	3 y	ES	-
T31	M	11 y	RMS	-
T32	F	3 y	RMS	-
T33	M	4 y	RMS	-

OS: osteosarcoma, OC: osteochondroma, WT: Wilms' tumor, ML: malignant lymphoma, ES: Ewing's sarcoma, RMS: rhabdomyosarcoma.




Fig. 2. Sensitivity of RT-PCR Technique for TH mRNA

Lane 1, marker; lane 2, one NB cell per 10 ES cells; lane 3, one NB cell per 10<sup>2</sup> ES cells; lane 4, one NB cell per 10<sup>3</sup> ES cells; lane 5, one NB cell per 10<sup>4</sup> ES cells; lane 6, one NB cell per 10<sup>5</sup> ES cells; lane 7, one NB cell per 10<sup>6</sup> ES cells. (A) Bands detected by electrophoresis. (B) Bands detected by Bioanalyzer. The 299 bp RT-PCR product for TH was detected by both electrophoresis and Bioanalyzer, and a 209 bp product for GAPDH was also seen.

that react selectively to cells of neuroectodermal origin, the diagnostic usefulness has been improved. However, the monoclonal antibodies often produce false positive results,<sup>29,30</sup> and the clinical importance of detecting positive cells as evidence of infiltration is still debated.<sup>31</sup> As NB has a specific catecholamine metabolism, it may be more useful to detect TH, which is the first and rate-limiting enzyme of catecholamine synthesis. We found that TH mRNA was expressed in all NB cell lines (100%) and in 23 of 25 (92%) clinical NB tumor samples. On the other hand, it was not expressed in any of the other cell lines and clinical tumor samples.

Thus, we found that TH mRNA is expressed specifically in NB, and this specific expression can be used to distinguish NB from SRCTs. TH mRNA can also be used as a tumor marker for the accurate diagnosis of NB.

The expression of TH mRNA did not correlate with the patient's age or sex, and it might not be a prognostic factor for NB patients.

Another important problem is determining whether tumor cell contamination exists when a patient's PBSC or BM is used for autologous transplantation. Our method can detect contamination of one cell in 10<sup>5</sup>.

In future, our method may be very useful for diagnosing NB patients and detecting minimal residual disease in clinical samples.

**Acknowledgements** We thank Dr. Toshimitsu Suzuki (Fukushima Medical University School of Medicine) (NB-

39), Dr. Jun-ichi Hata (Keio University School of Medicine, Department of Pathology) (NCR-EW2), and Dr. Yasuhide Hayashi (Tokyo University School of Medicine, Department of Pediatrics) (SCMS-ES1) for providing the cell lines.

This work was supported by a grant from the Ministry of Education, Culture, Sports, Science, and Technology of Japan to promote multi-disciplinary research projects.

REFERENCES

- Horowitz M. E., Malawer M. M., Delaney T. F., Tsokos M. G., "Principles and Practice of Pediatric Oncology," Lippincott Williams & Wilkins, Philadelphia, 1993, pp. 795-821.
- Sawada T., Hirayama M., Nakata T., Takeda T., Takasugi N., Mori T., Maeda K., Koide R., Hanawa Y., Tsunoda A., *Lancet*, 2, 271-273 (1984).
- Nagatsu T., *Cell. Mol. Neurobiol.*, 9, 313-321 (1989).
- Reynolds C. P., Seeger R. C., "Cancer Treatment, Part Neuroblastoma," ed. by Haskell C. M., Sanders, Philadelphia, 1995, pp. 860-871.
- Reynolds C. P., Biedler J. L., Spengler B. A., Reynolds D. A., Ross R. A., Frenkel E. P., Smith R. G., *J. Natl. Cancer Inst.*, 76, 375-387 (1986).
- Grima B., L'Amouroux A., Boni C., Julien J. F., Javoy-Agid F., Mallet J., *Nature (London)*, 326, 707-711 (1987).
- Horibe K., Fukuda M., Miyajima Y., Matsumoto K., Kondo M., Inaba J., Miyashita Y., *Med. Pediatr. Oncol.*, 36, 203-204 (2001).
- Cohn S. L., Moss T. J., Hoover M., Katzenstein H. M., Haut P. R., Morgan E. R., Green A. A., Kletzel M., *Bone Marrow Transplant.*, 20, 543-551 (1997).
- Leung W., Chen A. R., Klann R. C., Moss T. J., Davis J. M., Noga S. J., Cohen K. J., Friedman A. D., Small D., Schwartz C. L., Borowitz M. J., Wharam M. D., Pidas C. N., Long C. A., Karandish S., McMannis J. D., Kastan M. B., Civin C. I., *Bone Marrow Transplant.*, 22, 971-979 (1998).
- Evans A. E., D'Angio G. L., Randolph J., *Cancer*, 27, 374-378 (1981).
- Biedler J. L., Helson L., Spengler B. A., *Cancer Res.*, 33, 2643-2652 (1973).
- Suzuki T., Mugishima H., Chin M., Nagata T., Miyake M., Seeger R. C., Shimada H., Harada K., *Jpn. J. Pediatr. Oncol.*, 32, 136-140 (1995).
- Urano F., Umezawa A., Yabe H., Hong W., Yoshida K., Fujinaga K., Hata T., *Jpn. J. Cancer Res.*, 89, 703-711 (1998).
- Ida K., Kobayashi S., Taki T., Hanada R., Bessho F., Yamamori S., Sugimoto T., Ohki M., Hayashi Y., *Int. J. Cancer*, 63, 500-504 (1995).
- Soule H. D., Vazquez J., Long A., Albert S., Brennan M., *J. Natl. Cancer Inst.*, 51, 1409-1416 (1973).
- Piotr C., Nicoletta S., *Anal. Biochem.*, 162, 156-159 (1987).
- Takagi M., Nishioka M., Kakihara H., Kitabayashi M., Inoue H., Kawakami B., Oka M., Imanaka T., *Environ. Microbiol.*, 63, 4504-4510 (1997).
- Hashimoto H., Matsumoto T., Nishioka M., Yuasa T., Takeuchi S., Inoue T., Fujiwara S., Takagi M., Imanaka T., Kai Y., *J. Biochem. (Tokyo)*, 125, 983-986 (1999).
- Mizuguchi H., Nakatsuji M., Fujiwara S., Takagi M., Imanaka T., *J. Biochem. (Tokyo)*, 126, 762-768 (1999).
- Shirai C., *Jpn. Shounika Gakkai Zasshi.*, 101, 80-87 (1997).
- Bordow S. B., Norris M. D., Haber P.S., Marshall G. M., Haber M., *J. Clin. Oncol.*, 16, 3286-3294 (1998).
- Brodeur G. M., Seeger R. C., Schwab M., Varmus H. E., Bishop J. M., *Science*, 224, 1121-1124 (1984).
- Seeger R. C., Brodeur G. M., Sather H., Dalton A., Siegel S. E., Wong K. Y., Hammond D., *N. Engl. J. Med.*, 313, 1111-1116 (1985).
- Nakagawara A., Nakagawara-Arima M., Scarvada N. J., Azar C. G., Cantor A. B., Brodeur G. M., *N. Engl. J. Med.*, 328, 847-854 (1993).
- Suzuki T., Bogenmann E., Shimada H., Starm D., Seeger R., *J. Natl. Cancer Inst.*, 85, 377-384 (1993).
- Kogner P., Barbany G., Dominici C., Castello M. A., Raschella G., Persson H., *Cancer Res.*, 53, 2044-2050 (1993).
- Tanaka T., Sugimoto T., Sawada T., *Cancer*, 83, 1626-1633 (1993).

- 28) Doran J. F., Jackson P., Kynoch P. A., Thompson R. J., *J. Neurochem.*, 40, 1542—1547 (1983).
- 29) Matsumura T., Sugimoto T., Sawada T., Amagi T., Negoro S., Kemshead J. T., *Cancer Res.*, 47, 2924—2930 (1987).
- 30) Beck D., Maritaz O. P., Gross N., Farrot M., Vultier N., Bailly C., Villa I., Gentilhomme O., Philip T., *Eur. J. Pediatr.*, 147, 609—612 (1988).
- 31) Rogers D. W., Treleaven J., Kemshead J. T., Pritchard J., *J. Clin. Pathol.*, 42, 422—426 (1989).



## Establishment and characterization of a biphasic synovial sarcoma cell line, SYO-1

Akira Kawai<sup>a,\*</sup>, Noriko Naito<sup>b</sup>, Aki Yoshida<sup>b</sup>, Yuki Morimoto<sup>a</sup>, Mamoru Ouchida<sup>c</sup>,  
Kenji Shimizu<sup>c</sup>, Yasuo Beppu<sup>a</sup>

<sup>a</sup>Department of Orthopaedic Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan

<sup>b</sup>Science of Functional Recovery and Reconstruction, Graduate School of Medicine and Dentistry, Okayama University, 2-5-1 Shikata-cho, Okayama 700-8558, Japan

<sup>c</sup>Department of Molecular Genetics, Graduate School of Medicine and Dentistry, Okayama University, 2-5-1 Shikata-cho, Okayama 700-8558, Japan

Received 18 September 2003; received in revised form 19 September 2003; accepted 26 September 2003

### Abstract

We describe here the establishment of a new synovial sarcoma cell line, SYO-1, derived from a biphasic synovial sarcoma that developed in the groin of a 19-year-old female. The cell line was maintained for more than 70 passages (more than 24 months) in vitro. The SYO-1 cells in monolayer culture exhibited a spindle shape without conspicuous pleomorphism. Immunohistochemically, the cells were positive for vimentin, type IV collagen, S-100, mdm2, bcl-2, c-Met and c-Kit. Tumors developed by their implantation in nude mice histologically showed biphasic features that were composed of areas of fascicles of spindle cells and areas of compact proliferation of polygonal to ovoid cells, which occasionally formed epithelial plaque and expressed cytokeratin and EMA. SYO-1 cells harbored the characteristic t(X;18)(p11.2;q11.2) translocation by chromosome analysis and SYT-SSX2 chimeric transcript by RT-PCR. The SYO-1 cells, the first characterized cell line derived from biphasic synovial sarcoma retaining the characteristic genetic and phenotypic features of the tumor, will be useful for various investigations on synovial sarcoma, especially for its epithelial differentiation.

© 2003 Published by Elsevier Ireland Ltd.

**Keywords:** Synovial sarcoma; Biphasic; Epithelial differentiation; Cell line; SYT-SSX

### 1. Introduction

Synovial sarcoma is characterized by its unique feature that displays, to varying degrees, an epithelial phenotype despite its connective tissue origin. Although the tumor is named 'synovial' sarcoma

because of its histologic resemblance to normal synovial tissue, its exact histogenesis or line of differentiation remains unclear [1].

Cytogenetic and molecular studies have revealed that synovial sarcoma harbors a characteristic chromosomal translocation t(X;18)(p11.2;q11.2), which results in fusion of the SYT gene at 18q11 and either of the SSX1 or the SSX2 gene (or rarely, SSX4) at Xp11 [2–4]. Because of its presence in a high

\* Corresponding author. Tel.: +81-3-3542-2511; fax: +81-3-3542-3815.

E-mail address: [akawai@ncc.go.jp](mailto:akawai@ncc.go.jp) (A. Kawai).

proportion (greater than 90%) of synovial sarcomas, the generation of this translocation was suggested to be a primary causal event in tumor development. The SYT-SSX fusion product is thought to regulate the expression of a particular set of genes that may eventually develop the tumor. However, these putative SYT-SSX target genes and the mechanisms underlying oncogenesis are currently unknown.

Histologically, synovial sarcoma is classified into two major types, according to the presence or absence of gland-like structures: the biphasic type, which shows epithelial elements arranged in gland-like structures scattered against a uniform spindle-cell background, and the monophasic fibrous type, which is entirely composed of spindle tumor cells [1]. The type of the SSX genes involved in the SYT-SSX fusion transcript is associated with histopathological and clinical features of synovial sarcoma [5–8]. The majority of biphasic synovial sarcomas contain SYT-SSX1 fusion transcript, and patients with tumors having the SYT-SSX1 fusion transcript show a significantly reduced metastasis-free survival. The hepatocyte growth factor (HGF)/c-Met and stem cell factor (SCF)/c-Kit tyrosine kinase signaling systems also have been implicated in the histopathological features of synovial sarcoma, particularly in relation to its epithelial differentiation [9–12]. However, the mechanisms by which these genetic alterations produce phenotypically distinct types of tumors also remain unknown.

A cell line retaining the unique features of synovial sarcoma is valuable for studying these questions about the tumor. However, only a small number of established cell lines have been reported [13–19], and none of them are derived from biphasic synovial sarcoma, that is particularly useful for studying the epithelial differentiation of the tumor. We describe here the establishment of a new synovial sarcoma cell line, SYO-1, derived from a biphasic synovial sarcoma that exhibits the distinct features of the tumor.

## 2. Materials and methods

### 2.1. Establishment of cell line

A histologically confirmed biphasic synovial sarcoma which showed both features of proliferation

of spindle tumor cells and epithelial cells arranged in glandular structures that developed in the groin of a 19-year-old female was the original tumor (Fig. 1). At the time of definitive wide excision (no preoperative chemotherapy), a part of the surgically excised tumor was minced with scissors and seeded in 25-cm<sup>2</sup> tissue culture flasks (Becton Dickinson Lab., Bedford, MA) in a humidified atmosphere containing 5% CO<sub>2</sub> at 37 °C. The culture medium was Dulbecco's modified minimal essential medium supplemented with 10% fetal calf serum (FCS), 100 U/ml penicillin G and 100 µg/ml streptomycin (Invitrogen Co., Carlsbad, CA). When the cultured cells became confluent, the cells were dispersed with 0.25% trypsin solution and seeded in new flasks for passage. These procedures were serially performed until establishment of a cell line.

To determine the doubling time,  $1.0 \times 10^4$  cells were seeded in each well of 24-well dishes (Corning Inc., Corning, NY) with fresh medium containing 10% FCS and the number of viable cells was counted every 48 h for 12 days.

The tumorigenicity was examined after subcutaneous injection of  $5.0 \times 10^7$  cells into the back of BALB/c (nu/nu) nude mice (Charles River Japan, Inc., Yokohama, Japan).

### 2.2. Pathologic studies

Cells growing on chamber slides (Becton Dickinson Lab.) in addition to *in vivo* tumor tissues were examined. The cultured cells were fixed with 95% ethanol and the tumor tissues were fixed with 10% formalin. They were stained with hematoxylin and eosin and immunostained with the avidin–biotin–peroxidase complex (ABC) method (Vectastain Elite ABC kit; Vector Laboratories, Burlingame, CA). The HistoMouse™-Plus kit (Zymed Laboratories, San Francisco, CA) was used for detection of mouse primary antibodies on the tumors transplanted in nude mice.

The primary antibodies used were mouse monoclonal antibodies against vimentin (V9; Dako, Glostrup, Denmark), cytokeratin (AE1/AE3; Dako), epithelial membrane antigen (EMA; E29; Dako), type IV collagen ( $\times 100$ , Chemicon Int., Temecula, CA),  $\alpha$ -smooth muscle actin (1A4; Dako), muscle specific actin (HHF35; Dako), p53 (DO-7,  $\times 50$ ; Dako), mdm2 (SMP14,  $\times 50$ ; Dako), bcl-2 (124,  $\times 50$ ,



Fig. 1. Light microscopic findings of the original tumor ( $\times 200$ ). The tumor is composed of fascicles of spindle tumor cells (A) and areas of glandular differentiation (B). The epithelial cells arranged in glandular structures exhibit strong immunoreactivity for cytokeratin (C).

Dako), bcl-x (44,  $\times 50$ ; Transduction Lab., Lexington, KY), rabbit polyclonal antibodies against S-100 (Dako), bax (Ab-1,  $\times 50$ , Oncogene Research Products, San Diego, CA), c-Met ( $\times 50$ , IBL Lab., Gumma, Japan), c-Kit (C-19,  $\times 400$ ; Santa Cruz Biotechnology, Santa Cruz, CA), as well as goat polyclonal antibodies against HGF ( $\times 100$ ; R&D Systems, Minneapolis, MN) and SCF (N-19,  $\times 200$ , Santa Cruz Biotechnology). The antibodies of vimentin (V9), cytokeratin (AE1/AE3), EMA,  $\alpha$ -smooth muscle actin (1A4), muscle specific actin (HHF35), and S-100 were optimally diluted by the manufacture.

### 2.3. Cytogenetic analysis

Cultured cells at passage 27 were used for cytogenetic analysis. Chromosomal preparations were prepared by the air-drying method and karyotype analyses were performed by the conventional trypsin-Giemsa banding methods.

### 2.4. Reverse transcriptase polymerase chain reaction (RT-PCR)

The expressions of SYT-SSX fusion transcript and mRNAs of HGF, c-Met, SCF and c-Kit, were examined by RT-PCR. One microgram of total RNA from each material was reverse transcribed using the first strand cDNA synthesis kit (ReverTra Ace- $\alpha$ -<sup>TM</sup>; TOYOBO, Osaka, Japan). One microliter of the cDNA samples was applied to PCR in 20  $\mu$ l of reaction solution containing 0.4  $\mu$ M of specific primers, 10 mM Tris-HCl, 50 mM KCl, 1.5 mM MgCl<sub>2</sub>, 0.2 mM dNTP and 0.5 units of Taq polymerase (Takara, Ohtsu, Japan). The PCR profile comprised 35 cycles of denaturation at 94  $^{\circ}$ C for 1 min, annealing at 64  $^{\circ}$ C for 45 s, and extension at 72  $^{\circ}$ C for 1 min, with a final extension at 72  $^{\circ}$ C for 10 min.

To detect the SYT-SSX fusion transcripts, the following primers were used: forward primer (SYT): 5'-CAACAGCAAGATGCATACCA-3', reverse primers (SSX): 5'-CACTTGCTATGCACCTGATG-3', (SSX1): 5'-GGTGCAGTTGTTTCCCATCG-3', and (SSX2): 5'-GGCACAGCTCTTCCCATCA-3'. Using the consensus SYT-SSX primer pair, the PCR product had a 585-bp fragment, and using




Fig. 2. Light microscopic finding of SYO-1 cells *in vitro* (phase contrast microscope,  $\times 100$ ). SYO-1 cells are spindle-shaped and possess oval nuclei with small distinct nucleoli.

a SYT-SSX1 or SYT-SSX2 specific primer pair, it yielded a 331-bp fragment. To detect the HGF transcripts, the forward primer: 5'-GGGAAATGAGAAATGCAGCCAG-3', and the reverse primer: 5'-AGTTGTATTGGTGGGTGCTTC-3', were used to yield a 316-bp product. To detect the c-Met transcripts, the forward primer: 5'-CATGCCGACAAGTGCAGTA-3', and the reverse primer: 5'-TCTTGCCATCATTGTCCAA-3', were used to yield a 252-bp PCR product. Primers used for SCF were 5'-ATTCAAGAGCCCAGAACCCA-3' (forward) and 5'-CTGTTACCAGCCAATGTACG-3' (reverse), to yield 409- and 494-bp products. Primers used for c-Kit were 5'-GAGTTGGCCCTAGACTTAGA-3' (forward) and 5'-CCTGGAGTTGATGCAAGTT-3' (reverse), to yield a 749-bp PCR product.

As an internal control for PCR and for quality assessment of the RNAs, a 450-bp portion of the ubiquitously expressed glyceraldehyde 3-phosphate dehydrogenase (G3PDH) transcript was amplified with primers 5'-ACCACAGTCCATGCCATCAC-3' (forward) and 5'-TCCACCACCCTGTTGCTGTA-3' (reverse). In each PCR procedure, negative controls lacking RNA and lacking reverse transcriptase were included.

The PCR products were fractionated on 2.0% agarose gels and visualized with ethidium bromide.

### 3. Results

#### 3.1. Establishment of cell line

Three weeks after initial cultivation, small foci consisting of polygonal or spindle-shaped tumor cells appeared among the loosely proliferating fibroblastic cells and gradually increased in size. These foci were selectively digested with 0.25% trypsin solution for 5 min at 37 °C, and collected cells were plated in 25-cm<sup>2</sup> plastic flasks. Thereafter, they were serially subcultured at a dilution of 1:3 when they became confluent. After five to six passages, these cells began to grow stably, and thereafter could be subcultured every week. The cell line, designated as SYO-1 (Fig. 2), has been stably maintained for more than 70 passages (more than 24 months) *in vitro*. The doubling time of the cells in logarithmic growth phase was 28 h.

Immunohistochemically, the cultured SYO-1 cells were positive for vimentin, type IV collagen, S-100, mdm2, bcl-2, c-Met and c-Kit (Table 1). Cytokeratin and EMA were negative, while they gave positive results in the original tumor.

#### 3.2. Tumorigenicity

SYO-1 cells inoculated into the back of nude mice developed tumors within 2 months (5/5 mice).

Table 1  
Immunohistochemical staining of SYO-1 cells *in vitro* and *in vivo*

Antigen	SYO-1 cells		Original tumor
	<i>In vitro</i>	<i>In vivo</i>	
Vimentin	+	+	+
Cytokeratin	-	+	+
EMA	-	+	+
Type IV collagen	+	+	+
$\alpha$ -smooth muscle actin	-	-	-
Muscle specific actin	-	-	-
S-100	+	+	+
p53	-	-	-
mdm2	+	+	-
Bcl-2	+	+	+
Bcl-x	-	-	-
Bax	-	+	+
c-Met	+	+	+
c-Kit	+	+	+
HGF	-	-	-
SCF	-	-	-




Fig. 3. Light microscopic findings of the tumor produced by SYO-1 cells in vivo ( $\times 200$ ). The tumor shows biphasic features consisting of proliferation of spindle cells (A) and areas of polygonal epithelial cells (B).

The histologic features of these tumors resembled those of the original one. In some areas, the tumor consisted of proliferation of spindle cells having darkly stained nuclei and indistinct cytoplasm (Fig. 3A). Areas consisting of polygonal epithelial cells arranging around branching vessels and clefts were also observed (Fig. 3B).

Immunohistochemically, the tumor cells exhibited positive staining for vimentin, cytokeratin, EMA, type IV collagen, S-100, mdm2, bcl-2, bax, c-Met, and c-Kit (Table 1). The polygonal cells forming epithelial plaque were strongly positive for cytokeratin and EMA.

### 3.3. Cytogenetic findings

Chromosome analysis showed that consistent chromosomal abnormalities were present. The modal chromosome number was 47 (50 cells counted). G-banding analysis showed a characteristic reciprocal translocation involving chromosomes X and 18,  $t(X;18)(p11.2;q11.2)$ , in every metaphase cell examined (Fig. 4).

### 3.4. RT-PCR

On RT-PCR, the SYO-1 cells showed a 585-bp product using the consensus SYT-SSX primer pair and a 331-bp product using the SYT-SSX2 specific primer pair, confirming that this cell line had the SYT-SSX2 fusion transcript (Fig. 5). The SYO-1 cells also expressed c-Met (Fig. 6), SCF and c-Kit mRNA (Fig. 7).

## 4. Discussion

Histologically, synovial sarcoma is classified into two major types according to the presence or absence of epithelial elements arranged in gland-like structures: the biphasic type and the monophasic fibrous type. Immunohistochemically, both the epithelial markers cytokeratin and EMA and the mesenchymal marker vimentin are positive in the majority of synovial sarcomas, irrespective of the histologic subtypes [1]. Soft tissue sarcomas other than synovial sarcoma and epithelioid sarcoma ordinarily do not react with these epithelial markers. Based on these findings, some studies have considered synovial sarcoma as a carcinosarcoma-like tumor of soft tissue [20,21].

A recent progress in the understanding of the molecular mechanisms of tumorigenesis of synovial sarcoma is the discovery of the SYT-SSX fusion gene resulting from the chromosomal translocation  $t(X;18)(p11.2;q11.2)$  [2,3]. The aberrant SYT-SSX fusion protein was suggested to lead to neoplasia perhaps as a result of transactivation of other target genes not normally transcribed. Current evidence suggests that the SYT-SSX protein acts as a transcriptional co-factor, through a repression domain, SSX-RD, on the C-terminus of SSX and an activation domain, the QPGY domain, on the SYT




Fig. 4. A representative G-banding karyotype of SYO-1 cells, revealing 47, t(X;18) (p11.2;q11.2), -X or -Y, del (3) (p13q21), t(4;12)(q?31.3;q?24.1), t(6;6) (p23;q21), +7, +8, der(9) inv(9) (p12q13) t(9;15) (q32;q?13), t(10;20) (q22;q11.2), del(11) (q23), -13, der(15)t(9;15) (q32;q?13), +mar1. Arrows indicate abnormal chromosomes.

portion of the fusion protein [22,23]. However, the SYT-SSX fusion protein lacks a DNA-binding domain and the downstream transcriptional targets are presently unknown. Clinically, as this abnormality is specific for synovial sarcoma and has been observed in essentially all cases of the tumor, detection of this fusion either by chromosome analysis or by RT-PCR is useful for diagnosis of synovial sarcoma, especially for diagnostically difficult cases and tumors in unusual locations [24,25].

The pathognomonic SYT-SSX fusion appears to be related not only to oncogenesis, but also to the epithelial differentiation of synovial sarcoma [5,6]. The majority of biphasic synovial sarcomas contain the SYT-SSX1 fusion transcript, whereas the monophasic tumors have both fusion transcripts. This suggests a model in which SYT-SSX1 may be more




Fig. 5. Detection of SYT-SSX fusion transcripts by RT-PCR. M: 100-bp DNA ladder, 1: G3PDH, 2: SYT-SSX, 3: SYT-SSX1, 4: SYT-SSX2, 5: negative control. The SYO-1 cells express a 585-bp product with the SYT-SSX primer pair and a 331-bp product with the SYT-SSX2 specific primer pair, confirming the presence of the SYT-SSX2 fusion transcript.




Fig. 6. Detection of HGF and c-Met mRNA by RT-PCR. M: 100-bp DNA ladder, 1, 4: SYO-1 cells, 2, 5: KAO cells (clear cell sarcoma, HGF and c-Met positive control), 3, 6: negative control. SYO-1 cells generated a 252-bp c-Met product, but not a HGF product.




Fig. 7. Detection of SCF and c-Kit mRNA by RT-PCR. M: 100-bp DNA ladder, 1, 4: SYO-1 cells, 2, 5: SaOS2 cells (osteosarcoma, SCF and c-Kit positive control), 3, 6: negative control. SYO-1 cells generated both SCF products (409, 494 bp) and a 749-bp c-Kit product.

permissive for glandular morphogenesis or SYT-SSX2 may be a repressor of this differentiation pathway. However, the relation is not absolute, because rare SYT-SSX2-bearing biphasic tumors with clear glandular formation have been reported, as one case found in our previous study and the case of SYO-1 cells [24].

HGF/c-Met and SCF/c-Kit signaling systems were also reported to be involved in the epithelial differentiation of synovial sarcoma [9,10,12]. In line with the epithelial differentiating role of c-Met in the HGF/c-Met system, prominent expression of c-Met in the epithelial component of synovial sarcomas was reported [9,10]. On the other hand, Oda et al. [11]

reported that the co-expression of HGF and c-Met was correlated rather with progression of the tumors. A strong expression of other types of tyrosine kinase receptor c-Kit mainly in the epithelial component of synovial sarcoma was recently reported [12]. In SYO-1 cells, the expressions of c-Met and c-Kit were diffusely positive in the *in vitro* cultured conditions and were observed both in the epithelial and spindle-cell components in the *in vivo* tumors. The expression of SCF/c-Kit in synovial sarcoma is potentially interesting because the incorporation of this signaling system has also been observed in neuroectodermal tumors [26], which may share some phenotypic and genotypic characteristics with synovial sarcomas [27,28].

Further studies to clarify the link between the SYT-SSX fusion, HGF/c-Met and SCF/c-Kit signaling systems and the nature of synovial sarcoma will provide an important insight into the biology of the tumor. A cell line that retains the characteristic feature of synovial sarcoma will be valuable for these studies. Although a few cell lines have been established from synovial sarcoma [13–19], they have not always been fully characterized, and none of them are derived from biphasic synovial sarcoma (Table 2). A2243 was established in 1982 by Aaronson, but detailed characteristics of the cell line and the histological findings of original tumor have not been published. SYO-1 is the first well-characterized cell line derived from biphasic synovial sarcoma, which might be particularly useful for studying the epithelial differentiation of the tumor.

Four of nine reported synovial sarcoma cell lines showed SYT-SSX1 fusion transcript (containing HS-SY-3 that showed the truncated form of SYT-SSX1), and five cell lines expressed SYT-SSX2 fusion transcript (Table 2). Of the limited number of established cell lines, there was no clear relation between the types of fusion transcript and the histologic types of the tumor. In addition, the impact of SYT-SSX fusion types on the *in vitro* growth characters or *in vivo* tumorigenicity of the cells could not be answered with the available data about the established cell lines.

From the observation of the SN-SY-1 cells, Noguchi et al. [16] proposed that the *in vitro* growth pattern of synovial sarcoma had an epithelial morphology even though the original tumors were

Table 2  
Documented synovial sarcoma cell lines

Cell line	Age	Sex	Site	Histology	SYT-SSX	D.T. (hours)	Tumorigenicity
A2243 (Aronson, 1982) <sup>a</sup>	–	–	–	–	SYT-SSX2	–	–
SS255 (Reeves et al., 1989)	24	F	Thigh	Monophasic fibrous	SYT-SSX2	–	–
HS-SY-II (Sonobe et al., 1992)	43	M	Forearm	Monophasic fibrous	SYT-SSX1	60	Yes
CME-1 (Renwick et al., 1995)	18	F	Thigh	Monophasic fibrous	SYT-SSX2	–	–
SN-SY-1 (Noguchi et al., 1997)	21	M	Abdominal wall	Monophasic fibrous	SYT-SSX1	167	Yes
HS-SY-3 (Sonobe et al., 1999)	86	F	Popliteal fossa	Monophasic fibrous	SYT-SSX1, truncated	120	No
KU-SS-1 (Yakushiji et al., 2000)	27	F	Popliteal fossa	Monophasic fibrous	SYT-SSX2	93.8	Yes
FU-SY-1 (Nishio et al., 2002)	31	F	Supinator	Monophasic fibrous	SYT-SSX1	96	No
SYO-1 (Present study)	19	F	Groin	Biphasic	SYT-SSX2	28	Yes

<sup>a</sup> Data not published.

classified as monophasic fibrous type. Under the in vitro monolayer culture condition, the SYO-1 cells showed relatively uniform short spindle shapes. On the other hand, the in vivo tumors developed by their implantation showed biphasic features composed of areas of fascicles of spindle tumor cells and areas of a compact proliferation of polygonal to ovoid tumor cells, which occasionally formed epithelial plaque. Immunohistochemically, despite the lack of positivity for cytokeratin and EMA in the in vitro cultured SYO-1 cells, these antigens were positive in the original tumor and in vivo SYO-1 transplanted tumors. Although it is unclear why there were such discrepancies, alteration of the differentiation phenotypes depending on the surrounding conditions has frequently been observed in cultured human cells [14,16,18]. In KU-SS-1 cells, positive immunostaining for cytokeratin and EMA were observed only in the late passages in vitro [18].

Using microdissection techniques, Kasai et al. [29] and Nishio et al. [30] found that the SYT-SSX fusion transcripts were present in both epithelial and spindle cell areas of biphasic synovial sarcoma and suggested the monoclonarity of the tumor. The biphasic feature of the tumors developed by SYO-1 cells may support the theory that the tumor cells of biphasic synovial sarcoma have a dual differentiation capacity.

In conclusion, the current study established a cell line, SYO-1, derived from a biphasic synovial sarcoma. The SYO-1 cells, the first characterized cell line derived from biphasic synovial sarcoma retaining the characteristic genetic and phenotypic

features of the tumor, will be an important tool for various investigations of synovial sarcoma, especially for its epithelial differentiation.

## References

- [1] S.W. Weiss, J.R. Goldblum, *Soft Tissue Tumors*, Mosby, St Louis, MO, 2001.
- [2] J. Clark, P.J. Rocques, A.J. Crew, S. Gill, J. Shipley, A.M. Chan, et al., Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma, *Nat. Genet.* 7 (1994) 502–508.
- [3] A.J. Crew, J. Clark, C. Fisher, S. Gill, R. Grimer, A. Chand, et al., Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma, *Eur. Mol. Biol. Org. J.* 14 (1995) 2333–2340.
- [4] B. Skytting, G. Nilsson, B. Brodin, Y. Xie, J. Lundeberg, M. Uhlen, O. Larsson, A novel fusion gene, SYT-SSX4, in synovial sarcoma, *J. Natl Cancer Inst.* 91 (1999) 974–975.
- [5] A. Kawai, J. Woodruff, J.H. Healey, M.F. Brennan, C.R. Antonescu, M. Ladanyi, SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma, *N. Engl. J. Med.* 338 (1998) 153–160.
- [6] C.R. Antonescu, A. Kawai, D.H. Leung, F. Lonardo, J.M. Woodruff, J.H. Healey, M. Ladanyi, Strong association of SYT-SSX fusion type and morphologic epithelial differentiation in synovial sarcoma, *Diagn. Mol. Pathol.* 9 (2000) 1–8.
- [7] A. Mezzelani, L. Mariani, E. Tamborini, V. Agus, C. Riva, S. Lo Vullo, et al., SYT-SSX fusion genes and prognosis in synovial sarcoma, *Br. J. Cancer* 85 (2001) 1535–1539.
- [8] M. Ladanyi, C.R. Antonescu, D.H. Leung, J.M. Woodruff, A. Kawai, J.H. Healey, et al., Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients, *Cancer Res.* 62 (2002) 135–140.
- [9] T. Motoi, T. Ishida, M. Kuroda, H. Horiuchi, T. Oka, K. Matsumoto, et al., Coexpression of hepatocyte growth factor

- and c-Met proto-oncogene product in synovial sarcoma, *Pathol. Int.* 48 (1998) 769–775.
- [10] C. Kuhnen, E. Tolnay, H.U. Steinau, B. Voss, K.M. Muller, Expression of c-Met receptor and hepatocyte growth factor/scatter factor in synovial sarcoma and epithelioid sarcoma, *Virchows Arch.* 432 (1998) 337–342.
- [11] Y. Oda, A. Sakamoto, T. Saito, N. Kinukawa, Y. Iwamoto, M. Tsuneyoshi, Expression of hepatocyte growth factor (HGF)/scatter factor and its receptor c-Met correlates with poor prognosis in synovial sarcoma, *Hum. Pathol.* 31 (2000) 185–192.
- [12] E. Tamborini, D. Papini, A. Mezzelani, C. Riva, A. Azzarelli, G. Sozzi, et al., c-Kit and c-Kit ligand (SCF) in synovial sarcoma (SS): an mRNA expression analysis in 23 cases, *Br. J. Cancer* 85 (2001) 405–411.
- [13] B.R. Reeves, S. Smith, C. Fisher, W. Warren, J. Knight, C. Martin, et al., Characterization of the translocation between chromosomes X and 18 in human synovial sarcomas, *Oncogene* 4 (1989) 373–378.
- [14] H. Sonobe, Y. Manabe, M. Furihata, J. Iwata, T. Oka, Y. Ohtsuki, et al., Establishment and characterization of a new human synovial sarcoma cell line, HS-SY-II, *Lab. Invest.* 67 (1992) 498–505.
- [15] P.J. Renwick, B.R. Reeves, P. Dal Cin, C.D.M. Fletcher, H. Kempski, R. Sciort, et al., Two categories of synovial sarcoma defined by divergent chromosome translocation breakpoints in Xp11.2, with implications for the histologic sub-classification of synovial sarcoma, *Cytogenet. Cell Genet.* 70 (1995) 58–63.
- [16] S. Noguchi, T. Ueki, S. Kawauchi, T. Fukuda, H. Matsuura, T. Sonoda, M. Tsuneyoshi, Establishment and characterization of a new synovial sarcoma cell line, SN-SY-1: special reference to bcl-2 protein and SYT-SSX1 hybrid transcripts, *Int. J. Cancer* 72 (1997) 995–1002.
- [17] H. Sonobe, T. Takeuchi, S.B. Liag, T. Taguchi, K. Yuri, K. Shimizu, et al., A new human synovial sarcoma cell line, HS-SY-3, with a truncated form of hybrid SYT/SSX1 gene, *Int. J. Cancer* 82 (1999) 459–464.
- [18] T. Yakushiji, K. Yonemura, J. Tsuruta, K. Nishida, T. Kato, K. Takagi, Capacity for epithelial differentiation in synovial sarcoma: analysis of a new human cell line, *J. Clin. Pathol.* 53 (2000) 525–531.
- [19] J. Nishio, H. Iwasaki, M. Ishiguro, Y. Ohjimi, C. Fujita, T. Isayama, et al., Establishment of a new human synovial sarcoma cell line, FU-SY-1, that expresses c-Met receptor and its ligand hepatocyte growth factor, *Int. J. Oncol.* 21 (2002) 17–23.
- [20] M. Miettinen, I. Virtanen, Synovial sarcoma—a misnomer, *Am. J. Pathol.* 117 (1984) 18–25.
- [21] M. Leader, J. Patel, M. Collins, H. Kristin, Synovial sarcoma—true carcinosarcomas?, *Cancer* 59 (1987) 2096–2098.
- [22] H. Kato, A. Tjernberg, W. Zhang, A.N. Krutchinsky, W. An, T. Takeuchi, et al., SYT associates with human SNF/SWI complexes and the c-terminal region of its fusion partner SSX1 targets histones, *J. Biol. Chem.* 277 (2002) 5498–5505.
- [23] M. Nagai, S. Tanaka, M. Tsuda, S. Endo, H. Kato, H. Sonobe, et al., Analysis of transforming activity of human synovial sarcoma-associated chimeric protein SYT-SSX1 bound to chromatin remodeling factor hBRM/hSNF2 alpha, *Proc. Natl. Acad. Sci. USA* 98 (2001) 3843–3848.
- [24] N. Naito, A. Kawai, M. Ouchida, T. Dan'ura, Y. Morimoto, T. Ozaki, et al., A reverse transcriptase-polymerase chain reaction assay in the diagnosis of soft tissue sarcomas, *Cancer* 89 (2000) 1992–1998.
- [25] Y. Namba, A. Kawai, N. Naito, Y. Morimoto, S. Hanakawa, H. Inoue, Intraarticular synovial sarcoma confirmed by SYT-SSX fusion transcript, *Clin. Orthop.* 395 (2002) 221–226.
- [26] E. Ricotti, F. Fagioli, E. Garelli, C. Linari, N. Crescenzo, A.L. Horenstein, et al., c-kit is expressed in soft tissue sarcoma of neuroectodermic origin and its ligand prevents apoptosis of neoplastic cells, *Blood* 91 (1998) 2397–2405.
- [27] S. Nagayama, T. Katagiri, T. Tsunoda, T. Hosaka, Y. Nakashima, N. Araki, et al., Genome-wide analysis of gene expression in synovial sarcomas using a cDNA microarray, *Cancer Res.* 62 (2002) 5859–5866.
- [28] S.V. Allander, P.B. Illei, Y. Chen, C.R. Antonescu, M. Bittner, M. Ladanyi, P.S. Meltzer, Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation, *Am. J. Pathol.* 161 (2002) 1587–1595.
- [29] T. Kasai, S. Shimajiri, H. Hashimoto, Detection of SYT-SSX fusion transcripts in both epithelial and spindle cell areas of biphasic synovial sarcoma using laser capture microdissection, *Mol. Pathol.* 53 (2000) 107–110.
- [30] J. Nishio, H. Iwasaki, M. Ishiguro, Y. Ohjimi, T. Isayama, M. Naito, M. Kikuchi, Identification of SYT-SSX fusion transcripts in both epithelial and spindle cell components of biphasic synovial sarcoma in small tissue samples isolated by membrane-based laser microdissection, *Virchows Arch.* 439 (2001) 152–157.

## LETTER TO THE EDITOR

### Extraovarian Primary Peritoneal Carcinoma in a Child<sup>†</sup>

**Key words:** extraovarian primary peritoneal carcinoma; ovarian cancer; CA125; childhood cancer

Extraovarian primary peritoneal carcinoma (EOPPC) was first described in 1959 by Swerdlow [1]. It is an adenocarcinoma that develops from the peritoneum lining the pelvis and abdomen and is characterized by abdominal carcinomatosis, uninvolved or minimally involved ovaries, and no identifiable primary tumor. It accounts for ~10% of cases with a presumed diagnosis of ovarian cancer [2]. It is similar to ovarian serous carcinoma with respect to clinical presentation, histologic appearance, and response to chemotherapy [3]. The median age of recorded cases is 57–66 years [3] and there has been no prior report in a child. Our experience in such a case is of interest.

Our patient was 13-year-old girl, who was admitted to St. Luke's International Hospital, Tokyo, Japan, because of a huge abdominal mass. Her chief complaint was abdominal pain and constipation. A hard mass, about 5 cm × 6 cm in size, was palpable in the lower abdomen upon physical examination. Thyroid gland was not enlarged. Laboratory data were within normal limits except for CA125, which was 453.8 U/ml. Abdominal CT and MRI revealed a large, solid mass that occupied the pelvic cavity (Fig. 1), and no other tumor lesions were detected. The diagnosis before operation was a primary ovarian tumor. An open biopsy was performed and the histologic diagnosis was serous adenocarcinoma (Fig. 2). The size of the tumor did not decrease at all after three course of chemotherapy consisting of vindesine, doxorubicin, and fluorouracil (5-FU). Surgery performed 3 months after the biopsy removed the tumor together with the uterus, adnexa, and a part of the rectum and the sigmoid colon because the tumor directly invaded the uterus and large bowel. An endometrial cyst, 5 cm in diameter and attached to the neoplasm was also resected. The excised mass measured 9.0 cm × 6.0 cm × 4.5 cm (Fig. 3, arrowheads). The left ovary was 4.0 cm × 1.5 cm × 1.0 cm (Fig. 3, arrow) and no tumor cells were seen in the ovarian tissue. The size of the right ovary was 4.5 cm × 4.0 cm × 2.5 cm. There were adenocarcinoma components within the ovarian stroma. Since the ovary was not in continuity with the tumor, it was considered to be a metastatic lesion. Both fallopian tubes were normal. From the operative findings and histologic examination, it appeared that tumor originated from extraovarian tissue. It was, therefore, diagnosed as an EOPPC. Seventeen months after the operation, a vaginal recurrence was noted. Colpectomy was carried out and radiation therapy (total 50 Gy) was added. Six months after radiation, the tumor recurred in the pelvic cavity and abdominal wall. Management then became palliative to control pain by morphine sulfate, instead of aggressive chemotherapy and repeat surgery. She died 50 months after the diagnosis.

Most malignant ovarian tumors in adults are epithelial in type, but in children and adolescents, 60% are of germ cell




Fig. 1. Sagittal T<sub>2</sub>-weighted abdominal MRI. A large, solid tumor, 10 cm × 10 cm × 8 cm in size, occupied the pelvic cavity. A small, cystic mass lesion lay above the solid tumor (arrowhead). This mass turned out to be an endometrial cyst at surgery. A; anterior, P; posterior.

origin [4]. Ovarian carcinoma is rare, and extraovarian carcinoma is extremely rare in children. EOPPC should nonetheless be added to the differential diagnosis when a tumor occupying the abdominal cavity and considered of ovarian origin is encountered in a child.

The differential diagnosis should also include desmoplastic small round cell tumor in which elevated serum CA125 has been reported [5,6]. However, the pathologic findings of our case were completely different. No psammoma bodies or papillary and glandular structures are to be found in desmoplastic small round cell tumors.

It has been reported that levels of the tumor marker CA125 were elevated (>35 U/ml) in most of the EOPPC

<sup>†</sup>This manuscript was originally submitted to and accepted for publication in *Medical & Pediatric Oncology* by its Editor-in-Chief, Dr. G. D'Angio.

\*Correspondence to: Ryota Hosoya, MD, Department of Pediatrics, St. Luke's International Hospital, 9-1 Akashi-cho Chuo-Ku Tokyo 104-8560, Japan. E-mail: ryhosoya@luke.or.jp

Received 4 June 2002; Accepted 1 August 2002




Fig. 2. Hematoxylin and eosin stain. a: The tumor cells with nuclear atypia showed papillary growth (original magnification  $\times 200$ ). b: Psammoma bodies were seen in the tumor tissue (original magnification  $\times 400$ ).

patients [7,8]. In our patient, the CA125 levels correlated with the clinical status of the disease and response to therapy. This finding has also been reported in reference [7]. It is important to measure CA125 not only during chemotherapy but also thereafter.

The response to chemotherapy and the prognosis of EOPPC is said to be similar to serous ovarian carcinoma [3]. However, there have been some reports that the prognosis for EOPPC is worse than for ovarian serous cancers with comparable peritoneal spread [2,8]. Reported median survival durations vary between 7.0 and 27.8 months and 5-year survival rates range from 0 to 26.5% among EOPPC patients [3]. Our patient suffered repeated relapses in spite of tumor excision, chemotherapy, and radiation therapy. We chose "quality of life" management after chemotherapy and surgery failed to cure the tumor, so that the patient could go back to high school and travel abroad with her family.

In summary, we here report the first case of EOPPC in a child. Aggressive combined modality therapy failed to cure the girl.

Rie Shibata, MD  
Department of Pathology  
Keio University School of Medicine  
Tokyo, Japan

Hiroshi Matsufuji, MD  
Department of Surgery  
St. Luke's International Hospital  
Tokyo, Japan

Tsuyoshi Morimoto, MD  
Ryota Hosoya, MD  
Department of Pediatrics  
St. Luke's International Hospital  
Tokyo, Japan

Akinobu Araki, MD  
Department of Surgical Pathology  
Chiba Cancer Center  
Chiba, Japan

Jun-ichi Hata, MD  
National Research Institute  
for Child Health and Development  
Tokyo, Japan



Fig. 3. Gross appearance of the resected tumor and ovaries. The tumor (arrowheads) was solid and its color was yellow and white with degeneration and necrosis. It measured 9.0 cm  $\times$  6.0 cm  $\times$  4.5 cm. The left ovary (arrow) was 4.0 cm  $\times$  1.5 cm  $\times$  1.0 cm in size. No tumor cells were seen in the ovarian tissue.

## REFERENCES

1. Swerdlow M. Mesothelioma of the pelvic peritoneum reassembly papillary cystadenocarcinoma of the ovary. *Am J Obstet Gynecol* 1959;77:197-200.
2. Rothacker D, Mobius G. Varieties of serous surface papillary carcinoma of the peritoneum in Northern Germany: A thirty-year autopsy study. *Int J Gynecol Pathol* 1995;14:310-318.
3. Eltabbakh GH, Piver MS. Extraovarian primary peritoneal carcinoma. *Oncology* 1998;12:813-819.
4. Young RC, Perez CA, Hoskins WJ. Cancer of the ovary. In: De Vita VT, Jr., Hellmans S, Rosenberg SA, editors. *Cancer: Principles and practice of oncology*. Philadelphia: JB Lippincott; 1993. 1226 p.
5. Ordonez NG, Sahin AA. CA125 production in desmoplastic small round cell tumor: Report of a case with elevated serum levels and prominent signet ring cell morphology. *Hum Pathol* 1998;29:294-299.
6. Yoshizawa J, Maie M, Eto T, et al. A case of intra-abdominal desmoplastic small-round-cell tumor with elevated serum CA125. *Pediatr Surg Int* 2002; 18:238-240.
7. Altras MM, Aviram R, Cohen I, et al. Primary peritoneal papillary serous adenocarcinoma: Clinical and management aspects. *Gynecol Oncol* 1991; 40:230-236.
8. Killackey MA, Davis AR. Papillary serous carcinoma of the peritoneal surface: Matched-case comparison with papillary serous ovarian carcinoma. *Gynecol Oncol* 1993;51:171-174.

Original Article

## Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment

Wenlin Du,<sup>1</sup> Yutaka Hattori,<sup>2</sup> Akinori Hashiguchi,<sup>1</sup> Kensuke Kondoh,<sup>1</sup> Nobumichi Hozumi,<sup>3</sup> Yasuo Ikeda,<sup>2</sup> Michiie Sakamoto,<sup>1</sup> Jun-ichi Hata<sup>4</sup> and Taketo Yamada<sup>1</sup>

Departments of <sup>1</sup>Pathology and <sup>2</sup>Hematology, Keio University School of Medicine, <sup>4</sup>National Center for Child Health and Development, Tokyo and <sup>3</sup>Institute for Biological Sciences, Science University of Tokyo, Chiba, Japan

Angiogenesis in solid tumors is important to tumor growth, invasion and metastasis. Recently, it has been suggested that angiogenesis plays a certain role in the development of hematopoietic malignancies, including leukemia and multiple myeloma. We evaluated tumor angiogenesis in the bone marrow (BM) of multiple myeloma (MM) patients by calculating microvessel density (MVD) in needle-biopsy specimens obtained from 51 cases of untreated MM or monoclonal gammopathy of undetermined significance (MGUS). The MVD in the BM of donors for transplantation and patients with non-hematological diseases was calculated as a control. There was an obvious increase in MVD in the BM of MM patients, and the MVD correlated with the grade of myeloma cell invasion of the BM in the untreated MM cases. It was recently reported that thalidomide might be effective for the treatment of MM. We assessed the effect of thalidomide on angiogenesis in BM treatment of 11 patients with refractory MM. The concentration of M-protein in the serum or urine of seven of the 11 patients was reduced by at least 30% after thalidomide treatment, and MVD in the BM decreased in three of these seven cases in response to thalidomide. Increased plasma concentrations of basic fibroblast growth factor (FGF-2) and vascular endothelial growth factor (VEGF) were observed in all 11 cases before thalidomide administration and both levels were reduced after treatment with thalidomide. Augmented angiogenesis in the bone marrow of MM patients was confirmed in the present study. It seems that thalidomide is effective in the treatment of MM through the impairment of angiogenesis by decreasing FGF-2 and VEGF production. This is the first report on pathological evidence in the bone marrow of MM before and after thalidomide treatment, in Japan.

**Key words:** angiogenesis, CD34, fibroblast growth factor, multiple myeloma, thalidomide, vascular endothelial growth factor

Multiple myeloma (MM) is a plasma cell neoplasm that originates in the bone marrow and involves the entire skeleton. The myeloma cells synthesize large amounts of complete and/or incomplete immunoglobulins, which may cause a hyperviscosity syndrome, amyloidosis, and renal failure. Multiple myeloma accounts for approximately 10% of all hematological malignancies. Chemotherapy with melphalan and/or dexamethasone is effective in some cases but relapses often occur, and relapsed MM might become refractory to conventional chemotherapy.<sup>1</sup>

Angiogenesis is indispensable to growth, invasion and metastasis by solid tumors and occurs in other diseases, including rheumatoid arthritis, psoriasis, scleroderma and diabetic retinopathy.<sup>2–4</sup> Angiogenesis has been postulated to be regulated by a balance between certain angiogenic and antiangiogenic factors. Angiogenic factors include soluble factors, such as vascular endothelial growth factor (VEGF), acid and basic fibroblast growth factor (aFGF and bFGF or FGF-2), angiopoietin-1, hepatocyte growth factor (HGF) and interleukin-8 (IL-8), and adhesion molecules, such as integrins.<sup>5–8</sup> Vascular endothelial growth factor is considered an important vasculogenic mediator of embryonic and postnatal angiogenesis that functions in the promotion of endothelial cell growth and/or inhibition of apoptosis.<sup>9</sup> Elevated VEGF concentrations have been reported in several types of metastatic cancers, suggesting that it plays a role in cancer progression.<sup>10</sup> FGF-2 has been reported to be a potent stimulator of angiogenesis *in vitro* and is found in the serum and/or urine of patients with several types of cancer, including leukemias.<sup>11,12</sup> Angiogenesis has recently been reported in hematological malignancies, such as leukemia and myelodysplastic syndromes.<sup>11–18</sup> Vacca *et al.* reported finding positive correlations between increased bone marrow microvessel density (MVD) and both the plasma-cell labeling index and disease activity in MM patients.<sup>19</sup> The increased plasma or serum concentrations of FGF-2 and VEGF has been observed not only in solid tumors, such as prostate

Correspondence: Taketo Yamada, MD, Department of Pathology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. Email: taketo@sc.itc.keio.ac.jp

Received 3 July 2003 Accepted for publication 26 December 2003.

cancer and renal cancers, but also in hematological malignancies, such as acute lymphocytic leukemia, acute myeloleukemia, chronic myeloleukemia, and also MM.<sup>11,13,18</sup> Thus, it is critical to determine whether antiangiogenetic therapy will be useful for the treatment of hematological malignancies.

Thalidomide was introduced in the 1950s as a sedative, but was withdrawn from the market in the 1960s because of its teratogenicity.<sup>20</sup> Recently, thalidomide has been found to be effective against erythema nodosum leprosum,<sup>21</sup> graft-versus-host disease<sup>22</sup> and Crohn's disease.<sup>23</sup> An antiangiogenic function of thalidomide in a rabbit cornea micropocket assay was reported by D'Amato *et al.* in 1994.<sup>24</sup> Rajkumar *et al.* reported that tumor angiogenesis occurs in the bone marrow of MM patients and that thalidomide therapy improved the MM in some previously treated myeloma patients.<sup>25</sup>

We recently reported that the elevated level of plasma FGF-2 in MM patients correlated with increased disease activity.<sup>26</sup> Furthermore, we showed that thalidomide was effective for the treatment of refractory MM in Japan.<sup>27</sup> Hence, in the present study, we assessed the MVD of the bone marrow of untreated MM patients to confirm tumor angiogenesis in MM. We also investigated the effectiveness of thalidomide treatment for refractory MM patients and whether thalidomide administration altered tumor angiogenesis.

## MATERIALS AND METHODS

### Patients

To study angiogenesis in MM, we evaluated 51 bone marrow biopsy specimens from 51 untreated MM patients at Keio University Hospital. The clinical characteristics of the patients are shown in Table 1. The 51 patients consisted of 28 males and 23 females, and their median age was 62 years. Forty-two cases fulfilled the diagnostic criteria for MM of the South West Oncology Group (SWOG), and the other nine cases were diagnosed with a monoclonal gammopathy of undetermined significance (MGUS) based on the SWOG criteria.<sup>28</sup> The major subclass of immunoglobulin heavy chains was IgG (32 out of 51 cases). We used six bone marrow specimens, two from transplantation donors and four obtained at autopsy from patients with non-hematological diseases (pneumonia in two cases and cancer without bone marrow involvement in the other two cases).

To evaluate the effect of thalidomide on angiogenesis, we analyzed bone marrow biopsy specimens before and after thalidomide administration to 11 patients with refractory MM (six females and five males) who had been treated with conventional chemotherapy, such as vincristine, melpharan, prednisolone and dexamethasone (Table 2). Two patients

**Table 1** Clinical parameters of untreated patients

Number of patients	51
Average age (years)	62 (range, 37–88)
Male/Female	28/23
Subclass of Ig	
IgG	32
IgA	11
IgD	2
BJP	5
Nonsecretory	1
Stage (Durie-Salmon)	
1	15
2	6
3	21
MGUS	9

BJP, Bence Jones proteins; Ig, immunoglobulin; MGUS, monoclonal gammopathies of undetermined significance.

also received peripheral blood stem cell transplantation and Interferon alpha (IFN $\alpha$ ) before being treated with thalidomide. The disease of all 11 patients was categorized as Durie-Salmon stage 3 before treatment with thalidomide.<sup>29</sup>

### Immunohistochemistry

Sections of paraffin-embedded bone marrow specimens were stained by a standard indirect immunohistochemical technique with anti-CD34 mouse monoclonal antibody (Novocastra, Newcastle, UK) to highlight endothelial cells. The myeloma cells in the bone marrow were stained with antihuman plasma cell mouse monoclonal antibody (VS38c; DAKO, Glostrup, Denmark). The bone marrow specimens of the patients treated with thalidomide were also stained with anti-FGF-2 rabbit polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and anti-FGF Receptor 1 rabbit polyclonal antibody generated by immunizing a rabbit with a synthetic oligopeptide of human FGF Receptor 1.<sup>30</sup>

### Measurement of bone marrow microvessel density and the grading of myeloma cell invasion

All bone marrow biopsy specimens were evaluated for cellularity by light microscopy with a 10 $\times$  power objective lens. Five areas with high cellularity were randomly selected and examined with an 80 $\times$  power objective lens. Five fields were taken, with each field representing an area of 0.108 mm<sup>2</sup>. Individual microvessels (stained brown by immunohistochemistry anti-CD34 antibody) were counted in each fields and their density was calculated.

The grade of myeloma cell invasion in the bone marrow was determined by both hematoxylin-eosin (HE) staining and immunohistochemistry with anti-VS38c antibody. Invasion was graded as 'mild' if myeloma cells accounted for less